IO Biotech Goes From Breakthrough Designation to Bankruptcy
IO Biotech had a Breakthrough Therapy Designation, a Phase 3 with Merck, and Fast Company recognition. Then the FDA said no — and the company ceased to exist.
Category Voyager Articles
Trethera Takes Its Cancer Drug Into ALS With Mass General Collaboration
An oncology drug pivots into neurodegeneration — Trethera's TRE-515 enters expanded access in ALS patients at Massachusetts General Hospital.
Adcytherix Doses First Patient Just 21 Months After Incorporation
From founding to first patient in under two years — Adcytherix just entered the clinic with ADCX-020 after raising €135M. Its founders previously built the ADC company Lilly acquired.
Eli Lilly Buys Centessa for $6.3 Billion to Own the Orexin Franchise
Lilly didn't just buy a drug — they bought an entire orexin franchise. The $6.3B Centessa deal includes three OX2R agonists across clinical and preclinical stages.
TippingPoint Biosciences Raises $4.5M Seed to Target Pediatric Brain Cancer
TippingPoint just closed an oversubscribed $4.5M seed to go after DIPG — the deadliest childhood brain tumor — with a first-in-class epigenetic approach.
AI In Dermatology? Yeah, That’s A Thing Now. Thanks To Enveda Biosciences.
Enveda's ENV-294 hit 85% EASI reduction and 100% EASI-50 in Phase 1b for atopic dermatitis — and it's oral, first-in-class, and derived from plants.
Alltrna Sends the First tRNA Therapeutic Into Human Testing
Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.
Delonix Bioworks Begins Dosing Patients With Next-Gen MenB Vaccine in Australia
A Shanghai-based biotech is going global with an engineered MenB vaccine — and they're running the Phase 1 head-to-head against GSK's Bexsero.
Panacea Capital Forms Seismic Pharmaceuticals With Windtree’s Heart Failure Pipeline
Windtree sold its entire cardiovascular pipeline for pennies on the dollar. Now Panacea Capital is betting it can take istaroxime to Phase 3.
Aprea Therapeutics Reports Confirmed Response for WEE1 Inhibitor in Endometrial Cancer
Two confirmed partial responses, 50%+ tumor shrinkage, and a $30M oversubscribed raise. Aprea went from burning runway to suddenly very interesting.